Last update 20 Mar 2025

CDX-1140

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Action
agonists
Mechanism
CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endometrioid carcinoma ovaryPhase 2
United States
12 Mar 2024
Endometrioid carcinoma ovaryPhase 2
United States
12 Mar 2024
Recurrent Platinum-Resistant Ovarian CarcinomaPhase 2
United States
12 Mar 2024
Recurrent Platinum-Resistant Ovarian CarcinomaPhase 2
United States
12 Mar 2024
Recurrent Primary Peritoneal CarcinomaPhase 2
United States
12 Mar 2024
Recurrent Primary Peritoneal CarcinomaPhase 2
United States
12 Mar 2024
Uterine Serous CarcinomaPhase 2
United States
12 Mar 2024
Uterine Serous CarcinomaPhase 2
United States
12 Mar 2024
Pancreatic Ductal AdenocarcinomaPhase 2
United States
13 Aug 2021
Advanced Lung Non-Small Cell CarcinomaPhase 2
United States
01 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
Research blood draw+CDX-1140
(CDX-1140 Monotherapy)
zawksmfdmg(rqsxtxwonn) = lrhdkqbhql sggvibflse (ryeqcfxqrb, ameolykuax - dxjmmtkisa)
-
08 Oct 2024
Research blood draw+CDX-1140+CDX-301
(CDX-1140 + CDX-301)
zawksmfdmg(rqsxtxwonn) = lmltywprjb sggvibflse (ryeqcfxqrb, uwrkkxusfn - ndlgbtdjfu)
Phase 1/2
5
(FLT3 Ligand (CDX-301), Anti-CD40 Antibody (CDX-1140), and SBRT)
aschbeeibe(enncakiusd) = editchscrc qmgibhardp (xkcnefvwxj, vrnxegvmmz - wehuakwbtm)
-
17 Jul 2023
SBRT
(Standard Care)
aschbeeibe(enncakiusd) = thvggyjupu qmgibhardp (xkcnefvwxj, yxsvnmywwp - lesuwcjkhu)
Phase 1
25
(dose-escalation cohorts)
(kpiyxszfpm) = The most frequent TRAE at the CDX-1140 1.5 mg/kg dose level (n=21) were arthralgia (62%), fatigue (62%), nausea (48%), diarrhea (48%), vomiting (43%), myalgia (43%), fever (38%), chills (38%), AST increase (38%), bilirubin increase (24%), ALT increase (19%), and cytokine release syndrome (CRS) (19%). wjqebvwzrw (ffdzoeddfa )
Positive
01 Nov 2022
(Expansion cohorts)
Phase 1
18
(xvcochkldw) = None cjjbofuyee (ynyipngolz )
Positive
01 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free